The Potential of GABA-Mimetics in the Therapy of Extrapyramidal Disorders

  • G. Bartholini
  • K. G. Lloyd
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 16)


GABA mimetics inhibit extrapyramidal DA and ACh neurons and affeet an unknown system beyond both DA and ACh receptors, which is involved in extrapyramidal motor Outputs. Based on these data, the rationale is discussed for the clinical use of GABA mimetics in Huntington’s chorea, parkinsonian tremor, L-DOPA or neuroleptic-induced dyskinesias.


Tardive Dyskinesia Gaba Neuron Extrapyramidal Disorder Aminooxyacetic Acid Parkinsonian Tremor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Baraldi,M.,Grandison, L., Guidotti, A.: Distribution and metabolism of muscimol in the brain and other tissues of the rat. Neuropharmacology 18, 57–62 (1979).PubMedCrossRefGoogle Scholar
  2. Barbeau,A.: L-DOPA therapy in Parkinson’s disease: a critical review of nine years’ experience. Canad. Med. Assoc. J. 101, 59–68 (1969).PubMedGoogle Scholar
  3. Barbeau, A.: Neurological and Psychiatric side-effects of L-DOPA. Pharmacol. Therap. C 1, 475–494 (1976).Google Scholar
  4. Bartholini,G.,Stadler, H., Gadea-Ciria, M., Lloyd, K. G.: The use of the push-pull cannula to estimate the dynamus of acetylcholine and catecholamines within various brain areas. Neuropharmacology 15, 515–519(1976)PubMedCrossRefGoogle Scholar
  5. Bartholini,G, Scatton,B.,Zivkovic, B. Lloyd, K. G.: On the mode of action of SL 76 002, a new GABA receptor agonist. In: GABA-Neuro- transmitters, pp. 326–339. Copenhagen: Munksgaard. 1979 a.Google Scholar
  6. Bartholini, G., Lloyd, K. G., Worms, P., Constantinidis, J., Tissot, R.: GABA and GABA-ergic medication: relation to striatal dopamine function and parkinsonism. In: Advances in Neurology, Vol. 24, pp. 253–257. New York: Raven Press. 1979 b.Google Scholar
  7. Bernheimer,H, Birkmayer, W., Hornykiewicz, O., Jellinger, K., Seiteiberger, F.: Brain dopamine and the syndroms of Parkinson and Huntington. J. Neurol. Sci. 20, 415–455 (1973).PubMedCrossRefGoogle Scholar
  8. Calne,D. B.,Klawans, H. L.: Pathophysiology and pharmacotherapy of tremor. Pharmacol. Therap. C 2, 113–123 (1977).Google Scholar
  9. Calne,D. B.,Reid, J. L.: Antiparkinsonian drugs: pharmacological and therapeutic aspects. Drugs 4, 49–72 (1972).PubMedCrossRefGoogle Scholar
  10. Chase,T. N.,Tamminga, C. A.: GABA system partieipation in human motor, cognitive and neuroendoerine function. In: GABA-Neurotrans- mitters, pp. 283–294. Copenhagen: Munksgaard. 1979.Google Scholar
  11. Desarmenien,M.,Feltz, P., Headley, P. M., Santangelo, F.: Effects of various GABA-mimetics on dorsal ganglion (DRG) neurons: a neuro- physiological analysis. In: GABA and Other Inhibitory Neurotransmitters. Fayetteville: Ankho. 1980 (in press).Google Scholar
  12. Enna,S. J.,Snyder, S. H.: Properties of y-aminobutyric acid (GABA) receptor binding in rat brain synaptic membrane fractions. Brain Res. 100, 81–97 (1975).PubMedCrossRefGoogle Scholar
  13. Enna,S. J.,Stern, L. Z., Wastek, G. J., Yamamura, H. L.: Minireview: Neurobiology and pharmacology of Huntington’s disease. Life Sci. 20, 205–212 (1977).PubMedCrossRefGoogle Scholar
  14. Greenblatt,D. L.,Shader, R. I.; Anticholinergics. New Engl. J. Med. 288, 1215–1219 (1973).PubMedCrossRefGoogle Scholar
  15. Hornykiewicz, O.: Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Revs 18, 925–964 (1966).Google Scholar
  16. Iversen,L. L.,Bird, E. D., Spokes, E., Nicholson, S. H., Suckling, C. J..: Agonist speeifity of GABA binding sites in human brain and GABA in Huntington’s disease and schizophrenia. In: GABA-Neurotransmitters, pp. 179–190. Copenhagen: Munksgaard. 1979.Google Scholar
  17. Kaariainen, I.; Effect of aminooxyacetic acid and baclofen on the catalepsy and on the increase of mesolimbic and striatal dopamine turnover induced by haloperidol in rats. Acta Pharmacol. Toxicol. 39, 393–400 (1976).CrossRefGoogle Scholar
  18. Keller,H. H.,Schaffner, R., Haefely, W.: Interaction of benzodiazepines with neuroleptics at central dopamine neurons. Naunyn-Schmiedeberg’s Arch. Pharmacol. 294, 1–4 (1976).Google Scholar
  19. Lloyd,K. G.: Indications for GABA neuron dysfunetion in mental disease. In: Enzymes and Neurotransmitters in Mental Disease. New York: RavenPress.1980(inpress).The Potential of GABA Mimetics in the Therapy of Extrapyramidal Disorders 237Google Scholar
  20. Lloyd,K. G.,Davidson, L.: [3H]GABA binding in brains from Huntington’s chorea patients: altered regulation by phospholipids. Science 205, 1147–1149(1979).PubMedCrossRefGoogle Scholar
  21. Lloyd,K. G.,Dreksler, S.: An analysis of [3H] Gamma-aminobutyric acid (GABA) binding in the human brain. Brain Res. 163, 77–87 (1979).PubMedCrossRefGoogle Scholar
  22. Lloyd,K. G.,Hornykiewicz, O.: L-glutamic acid decarboxylase in Parkinson’s disease: effect of L-DOPA therapy. Nature243, 521–523 (1973).PubMedCrossRefGoogle Scholar
  23. Lloyd,K. G.,Worms, P.: Sustained gamma-aminobutyric acid receptor Stimulation and chronic neuroleptic effects. In: Long-Term Effects of Neuroleptics. New York: Raven Press. 1980 (in press).Google Scholar
  24. Lloyd,K. G.,Davidson, L., Hornykiewicz, O.; The neurochemistry of Parkinson’s disease: effect of L-DOPA therapy. J. Pharmacol. Exp. Therap. 195, 453–464 (1975).Google Scholar
  25. Lloyd,K. G.,Shemen, L., Hornykiewicz, O.; Distribution of high affinity sodium-independent (3H)gamma-aminobutyric acid (3H-GABA) binding in the human brain: alterations in Parkinson’s disease. Brain Res. 127, 269–278 (1977 a).CrossRefGoogle Scholar
  26. Lloyd,K. G.,Dreksler, S., Bird, E. D.: Alterations in 3H-GABA binding in Huntington’s chorea. Life Sci. 21, 747–754 (1977 b).PubMedCrossRefGoogle Scholar
  27. Lloyd,K. G.,Worms, P., Depoortere, H., Bartholini, G.: Pharmacological profile of SL 76 002, a new GABA mimetic drug. In: GABA-Neuro- transmitters, pp. 308–325. Copenhagen: Munksgaard. 1979.Google Scholar
  28. Lloyd,K. G.,Worms, P., Zivkovic, B., Scatton, B., Bartholini, G.: Inter- action of GABA mimetics with nigro-striatal dopamine neurons. In: GABA and Other Inhibitory Transmitters. Fayetteville: Ankho. 1980 (in press).Google Scholar
  29. Maggi,A.,Enna, S. J.: Characteristics of muscimol accumulation in mouse brain after systemic administration. Neuropharmacology 18, 361–366 (1979).PubMedCrossRefGoogle Scholar
  30. Morselli,P. L.,Bossi, L., Henry, J. P., Zarifian, E., Bartholini, G.: On the therapeutic action of SL 76 002, a new GABA mimetic agents: preliminary observations in neuropsychiatric disorders. In: GABA and Other Inhibitory Neurotransmitters. Fayetteville: Ankho. 1980 (in press).Google Scholar
  31. Olsen,R. W.,Wan Ness, P. C., Tourtelotte, W. W.: Gamma-aminobutyric acid receptor binding curves for human brain regions: comparison of Huntington’s disease and normal. In: Huntington’s Disease, pp. 697–704. New York: Raven Press. 1979.Google Scholar
  32. Perry,T. L.,MacLeod, P. M., Hansen, S.: Treatment of Huntington’s chorea with isoniazid. New Engl. J. Med. 297, 840 (1977).PubMedCrossRefGoogle Scholar
  33. Reisine,T. D.,Beaumont, K.,Bird, E. D., Spokes, E., Yamamura, H. I.; Huntington’s disease: alterations in neurotransmitter receptor binding in the human brain. In: Huntington’s Disease, pp. 717–726. New York: Raven Press. 1979.Google Scholar
  34. Scatton,B.,Bartholini, G.: Modulation of cholinergic transmission in the rat brain by GABA mimetics. In: GABA and Other Inhibitory Transmitters. Fayetteville: Ankho. 1980 (in press).Google Scholar
  35. Schwanz,W.J.,Sharp, F. R., Gunn, R. H., Evarts, E. V.: Lesions of ascending dopaminergic pathways decrease forebrain glucose uptake. Nature261, 155–157 (1976).CrossRefGoogle Scholar
  36. Tarsy,D ., Baldessarini, R.J.: The pathophysiologic basis of tardive dyskinesia. Biol. Psychiat. 12, 431–450 (1977).PubMedGoogle Scholar
  37. Worms,P.,Lloyd, K. G.: Biphasic effects of direct, but not indirect, GABA mimetics and antagonists on haloperidol-induced catalepsy. Naunyn- Schmiedeberg’s Arch. Pharmacol. 1980 (in press).Google Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • G. Bartholini
    • 1
  • K. G. Lloyd
    • 1
  1. 1.Research DepartmentSynthélabo-L.E.R.S.ParisFrance

Personalised recommendations